Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Systemic drug administration faces challenges in reaching target sites, leading to toxicity.
• Targeted drug delivery offers a promising strategy to improve efficacy and reduce side effects.
• Ligand-based targeting leverages high-affinity binding to specific cell surface receptors.

Purpose of the Study:

• To review the importance of binding affinity (K D) in selecting ligands for nanoparticle targeting.
• To critically compare various targeting ligand formats, including monoclonal antibodies, antibody derivatives, peptides, aptamers, DARPins, and small molecules.
• To assess these targeting strategies based on parameters like molecular size, immunogenicity, production cost, and clinical profiles.

Main Methods:

• Literature review focusing on binding affinities of different targeting ligands.
• Comparative analysis of ligand formats based on key parameters: molecular size, immunogenicity, cost, clinical data, selectivity, and toxicity.
• Evaluation of targeted approaches against conventional treatments.

Main Results:

• Binding affinity (K D) is a critical factor in ligand selection for nanoparticle targeting.
• Different ligand types (antibodies, peptides, aptamers, etc.) offer distinct advantages and disadvantages regarding size, immunogenicity, and cost.
• Targeted delivery systems demonstrate potential for improved selectivity and reduced toxicity compared to non-targeted methods.

Conclusions:

• The choice of targeting ligand significantly impacts the success of nanoparticle-based drug delivery.
• A comprehensive evaluation of ligand properties, including binding affinity and other parameters, is essential for optimal targeting strategy development.
• Targeted drug delivery holds significant promise for enhancing therapeutic outcomes and patient safety.